bevacizumab (avastin): 2 year results in choroidal neovascularization (cnv) secondary to pathologic...
TRANSCRIPT
![Page 1: Bevacizumab (Avastin): 2 year results in choroidal neovascularization (CNV) secondary to pathologic myopia (PM). regory S. Brinton; Sayed S E H Saif; M](https://reader036.vdocument.in/reader036/viewer/2022062511/551669e05503469d698b54e0/html5/thumbnails/1.jpg)
Bevacizumab (Avastin): 2 year
results in choroidal
neovascularization (CNV)
secondary to pathologic myopia
(PM).
regory S. Brinton; Sayed S E H Saif; M. Yasser S. Saif; Ahmed T.S. Saif
No Financial Interest
![Page 2: Bevacizumab (Avastin): 2 year results in choroidal neovascularization (CNV) secondary to pathologic myopia (PM). regory S. Brinton; Sayed S E H Saif; M](https://reader036.vdocument.in/reader036/viewer/2022062511/551669e05503469d698b54e0/html5/thumbnails/2.jpg)
M. Yasser S. Saif ,MD* Ahmed T.S. Saif, MD**
Gregory S. Brinton, MD***Sayed S E H Saif, MD****
*Assistant Prof of ophthalmology Beni sueif university** lecturer of ophthalmology Fayoum university***Prof of ophthalmology Utah university****Prof of ophthalmology Cairo university
![Page 3: Bevacizumab (Avastin): 2 year results in choroidal neovascularization (CNV) secondary to pathologic myopia (PM). regory S. Brinton; Sayed S E H Saif; M](https://reader036.vdocument.in/reader036/viewer/2022062511/551669e05503469d698b54e0/html5/thumbnails/3.jpg)
• PURPOSE: To evaluate the safety and efficacy of intravitreal bevacizumab in the treatment of choroidal neovascularization (CNV) secondary to pathologic myopia (PM).
• DESIGN: Prospective, consecutive, nonrandomized, interventional case series.
![Page 4: Bevacizumab (Avastin): 2 year results in choroidal neovascularization (CNV) secondary to pathologic myopia (PM). regory S. Brinton; Sayed S E H Saif; M](https://reader036.vdocument.in/reader036/viewer/2022062511/551669e05503469d698b54e0/html5/thumbnails/4.jpg)
• PARTICIPANTS: Thirty four eyes of 34 patients with CNV secondary to PM.
• METHODS: Consecutive patients with subfoveal or juxtafoveal CNV secondary to PM were recruited prospectively to receive an intravitreal injection of bevacizumab. Additional injections were performed in eyes with persistent CNV leakage after 2-6 month durations.
• Patients were followed up for 24 months, and BCVA, changes in FFA and OCT results were assessed.
![Page 5: Bevacizumab (Avastin): 2 year results in choroidal neovascularization (CNV) secondary to pathologic myopia (PM). regory S. Brinton; Sayed S E H Saif; M](https://reader036.vdocument.in/reader036/viewer/2022062511/551669e05503469d698b54e0/html5/thumbnails/5.jpg)
RESULTS: • The mean spherical equivalent
refractive error of the 34 eyes was -10.56+/-3.49 D (range, -6.0D to -19.0D).
• follow-up period : 24 months. • BCVA
– improved in 24 eyes(70.6%) – the same in 6 eyes (17.6%)– decreased in 4(11.8%) eyes.
BCVA
improvedsamedecreased
3 2 1 0 -1 -2 -30
2
4
6
8
10
BCVA lines Gained
![Page 6: Bevacizumab (Avastin): 2 year results in choroidal neovascularization (CNV) secondary to pathologic myopia (PM). regory S. Brinton; Sayed S E H Saif; M](https://reader036.vdocument.in/reader036/viewer/2022062511/551669e05503469d698b54e0/html5/thumbnails/6.jpg)
Case received 3 injectionsin 2 years
and the CNV is still progressive
![Page 7: Bevacizumab (Avastin): 2 year results in choroidal neovascularization (CNV) secondary to pathologic myopia (PM). regory S. Brinton; Sayed S E H Saif; M](https://reader036.vdocument.in/reader036/viewer/2022062511/551669e05503469d698b54e0/html5/thumbnails/7.jpg)
2007 Feb 2008
Dec 2008 2009
BCVA improved 3 lines from base line
![Page 8: Bevacizumab (Avastin): 2 year results in choroidal neovascularization (CNV) secondary to pathologic myopia (PM). regory S. Brinton; Sayed S E H Saif; M](https://reader036.vdocument.in/reader036/viewer/2022062511/551669e05503469d698b54e0/html5/thumbnails/8.jpg)
• The OCT results also showed significant reduction in thickness after treatment.
• No systemic complications were noted after intravitreal injections.
• One eye (2.9%) had an endophthalmitis and resolved on medical treatment. Pre injection 18 month (6
injections
![Page 9: Bevacizumab (Avastin): 2 year results in choroidal neovascularization (CNV) secondary to pathologic myopia (PM). regory S. Brinton; Sayed S E H Saif; M](https://reader036.vdocument.in/reader036/viewer/2022062511/551669e05503469d698b54e0/html5/thumbnails/9.jpg)
• Thirty eyes (88.2%) received multiple injections (2-6 injections)
• The injection interval varies between 2-13 months
![Page 10: Bevacizumab (Avastin): 2 year results in choroidal neovascularization (CNV) secondary to pathologic myopia (PM). regory S. Brinton; Sayed S E H Saif; M](https://reader036.vdocument.in/reader036/viewer/2022062511/551669e05503469d698b54e0/html5/thumbnails/10.jpg)
CONCLUSIONS:
• The 24-month outcomes suggest intravitreal bevacizumab to be a promising treatment method for CNV secondary to PM, resulting in both visual and anatomic improvements.